Figure 3.
Figure 3. Effects of cytokine-neutralizing antibodies and p38 inhibitor on the phenotype of MoDCs from myeloma patients. (A) Representative histograms showing the expression of CD1a, CD40, CD80, HLA-ABC, and HLA-DR on patient-derived mature MoDCs generated in cultures with or without addition, individually or in a combination (Ab comb), of all 3 neutralizing antibodies (Ab; 10 μg/mL) to IL-6, IL-10, or TGF-β1; p38 inhibitor; or p38 inhibitor and IL-6 antibody. Numbers inside the histograms represent the MFI. (B) Pooled data depicting the expression (MFI) of CD1a, CD40, CD80, HLA-ABC, and HLA-DR on the cells from all tested myeloma patients (n = 6) treated with IL-6 antibody, p38 inhibitor, or both. Bars indicate the mean MFI. *P values less than .05; **P values less than .01.

Effects of cytokine-neutralizing antibodies and p38 inhibitor on the phenotype of MoDCs from myeloma patients. (A) Representative histograms showing the expression of CD1a, CD40, CD80, HLA-ABC, and HLA-DR on patient-derived mature MoDCs generated in cultures with or without addition, individually or in a combination (Ab comb), of all 3 neutralizing antibodies (Ab; 10 μg/mL) to IL-6, IL-10, or TGF-β1; p38 inhibitor; or p38 inhibitor and IL-6 antibody. Numbers inside the histograms represent the MFI. (B) Pooled data depicting the expression (MFI) of CD1a, CD40, CD80, HLA-ABC, and HLA-DR on the cells from all tested myeloma patients (n = 6) treated with IL-6 antibody, p38 inhibitor, or both. Bars indicate the mean MFI. *P values less than .05; **P values less than .01.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal